CoChat

Aberrant Methylation of DPYD Promoter, DPYD Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer Cells

Noguchi, Takuya, Tanimoto, Keiji, Shimokuni, Tatsushi, Ukon, Kei, Tsujimoto, Hiroaki, Fukushima, Masakazu, Noguchi, Tsuyoshi, Kawahara, Katsunobu, Hiyama, Keiko, Nishiyama, Masahiko · 2004 · Clinical Cancer Research
Cited by 59

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Purpose: Dihydropyrimidine dehydrogenase (DPD), the initial rate-limiting enzyme in the degradation of 5-fluorouracil (5-FU), is known to be a principal factor in clinical responses to the anticancer agent 5-FU, and various reports have clearly demonstrated that DPD activity is closely correlated to mRNA levels. However, the regulatory mechanisms of DPD gene (DPYD) expression remain unclear. In this study, the regulatory mechanisms have been intensively studied. Experimental Design and Results: A subcloned 3.0-kb fragment of the 5′ region of DPYD contains a total of 60 CpG sites, suggesting that methylation status may affect the repression of DPYD. The clone showed various promoter activities that were largely correlated with mRNA levels in most cell lines, except HSC3 and HepG2. Bisulfite sequencing analysis revealed that various CpG sites around the transcription start site were abnormally methylated in cells with low DPYD expression: Reversal of hypermethylation by 5-azacytidine treatment significantly increased DPYD expression in HSC3 and HepG2 cells that showed strong promoter activity. In HepG2, in vitro methylation of the DPYD promoter directly decreased promoter activity, and 5-azacytidine treatment restored higher DPYD expression in a dose- and time-dependent manner, along with decreased sensitivity to 5-FU. Conclusions: We found that DPD activity was controlled, at least in part, at the transcription level of DPYD and that aberrant methylation of the DPYD promoter region acted as one of the repressors of DPYD expression and affected sensitivity to 5-FU in cancer cells. Our new results could lead to a more precise understanding of the molecular basis of 5-FU response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-0337

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 59

Metadata

Authors
Noguchi, T., Tanimoto, K., Shimokuni, T., Ukon, K., Tsujimoto, H., Fukushima, M., Noguchi, T., Kawahara, K., Hiyama, K., & Nishiyama, M.
Venue
Clinical Cancer Research
Published
2004-10-15
Volume
10
Issue
20
Pages
7100-7107
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1979576635
Cited by
59
References
1
FWCI
1.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aberrant Methylation of DPYD Promoter, DPYD Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0337
The paper
Noguchi, T., Tanimoto, K., Shimokuni, T., Ukon, K., Tsujimoto, H., Fukushima, M., Noguchi, T., Kawahara, K., Hiyama, K., & Nishiyama, M. (2004). Aberrant Methylation of DPYD Promoter, DPYD Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0337

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.